Shen Peipei, Xu Yu, Zhu Jiahao, Qian Danqi, Yang Bo, Mao Yong, Ji Shengjun, Gu Ke, Zhao Yutian
Department of Radiotherapy and Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, China; Wuxi Clinical Cancer Center, Wuxi, China.
Department of Oncology, The Affiliated Hospital of Jiangnan University, Wuxi, China; Wuxi Clinical Cancer Center, Wuxi, China.
Biomol Biomed. 2025 Apr 3;25(5):1000-1008. doi: 10.17305/bb.2024.10658.
This study aimed to investigate the prognostic value of the pan-immune-inflammation value (PIV) in patients with locally advanced rectal cancer (LARC) who received neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision. We retrospectively collected and analyzed the clinicopathological data of 215 resected LARC patients. X-tile software was used to determine the optimal threshold value for PIV in predicting overall survival (OS). The predictive ability of PIV for pathological complete regression (pCR), OS, and disease-free survival (DFS) was evaluated and compared with other inflammation markers. Univariate and multivariate logistic regression analyses for pCR and Cox regression analyses for OS and DFS were conducted. The optimal threshold value for PIV was determined to be 454.7 based on the X-tile software. Patients were then categorized into low (≤ 454.7) and high (> 454.7) PIV groups comprising 153 and 62 patients, respectively. PIV demonstrated superior predictive ability for pCR, OS, and DFS compared to other inflammation markers. LARC patients with low PIV had significantly higher pCR (P = 0.029), OS (P = 0.002), and DFS (P = 0.001) rates compared to those with high PIV. Multivariate regression analysis identified PIV as an independent prognostic factor for pCR (odds ratio = 0.32; 95% confidence interval [CI], 0.10-0.80; P = 0.014), OS (hazard ratio = 3.08; 95% CI, 1.77-5.35; P = 0.001), and DFS (hazard ratio = 2.53; 95% CI, 1.58-4.06; P = 0.002). This study confirmed that preoperative PIV could serve as a useful independent prognostic factor in LARC patients treated with nCRT.
本研究旨在探讨泛免疫炎症值（PIV）在接受新辅助放化疗（nCRT）后行全直肠系膜切除术的局部晚期直肠癌（LARC）患者中的预后价值。我们回顾性收集并分析了215例接受手术切除的LARC患者的临床病理资料。使用X-tile软件确定PIV预测总生存期（OS）的最佳阈值。评估PIV对病理完全缓解（pCR）、OS和无病生存期（DFS）的预测能力，并与其他炎症标志物进行比较。对pCR进行单因素和多因素逻辑回归分析，对OS和DFS进行Cox回归分析。根据X-tile软件，PIV的最佳阈值确定为454.7。然后将患者分为低（≤454.7）PIV组和高（>454.7）PIV组，分别包括153例和62例患者。与其他炎症标志物相比，PIV对pCR、OS和DFS具有更好的预测能力。低PIV的LARC患者的pCR（P = 0.029）、OS（P = 0.002）和DFS（P = 0.001）率显著高于高PIV患者。多因素回归分析确定PIV是pCR（比值比= 0.32；95%置信区间[CI]，0.10 - 0.80；P = 0.014）、OS（风险比= 3.08；95% CI，1.77 - 5.35；P = 0.001）和DFS（风险比= 2.53；95% CI，1.58 - 4.06；P = 0.002）的独立预后因素。本研究证实，术前PIV可作为接受nCRT治疗的LARC患者有用的独立预后因素。
